EMP3 and glioma: Given the limited evidence that EMP3 may be a biomarker to predict the prognosis in gliomas, our study was performed to determine the relationship between EMP3 and immune infiltration and clinical outcomes and to establish a practical nomogram predictive model to guide the clinical therapy and assess prognosis.